Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$3.38 -1.2%	$3.77	$1.60 ▼ $16.55	$251.01M	1.17	945,306 shs	497,034 shs
NPCE NeuroPace	$8.66 +5.0%	$9.72	$5.45 ▼ $18.98	$286.48M	1.89	277,205 shs	506,772 shs
RXST RxSight	$8.45 -4.1%	$10.06	$6.32 ▼ $58.23	$345.74M	1.16	1.04 million shs	1.08 million shs
VANI Vivani Medical	$1.22 +0.8%	$1.35	$0.91 ▼ $1.80	$72.27M	2.99	106,998 shs	29,745 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	-7.32%	-14.07%	-18.57%	+39.02%	-75.85%
NPCE NeuroPace	-2.02%	-9.64%	-8.94%	-54.50%	+16.20%
RXST RxSight	+3.77%	+19.86%	+19.86%	-44.97%	-83.32%
VANI Vivani Medical	-2.42%	-4.72%	-21.94%	+7.08%	-11.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	1.5494 of 5 stars	3.6	1.0	1.9	0.8	0.0
NPCE NeuroPace	3.2801 of 5 stars	3.4	3.0	3.0	3.3	0.6
RXST RxSight	1.5148 of 5 stars	3.0	1.0	1.6	1.7	0.6
VANI Vivani Medical	2.152 of 5 stars	3.5	3.0	1.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	272.02% Upside
NPCE NeuroPace	2.83	Moderate Buy	$16.60	91.66% Upside
RXST RxSight	1.91	Reduce	$10.00	18.13% Upside
VANI Vivani Medical	3.00	Buy	$4.00	229.22% Upside

Current Analyst Ratings Breakdown

Latest VANI, RXST, NPCE, and CATX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NPCE NeuroPace	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	NPCE NeuroPace	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $15.00
8/8/2025	RXST RxSight	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
8/8/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $8.00
8/8/2025	RXST RxSight	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $11.00
7/15/2025	RXST RxSight	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $9.00
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	RXST RxSight	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$24.00 ➝ $9.00
7/9/2025	RXST RxSight	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $9.00
7/9/2025	RXST RxSight	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$18.00 ➝ $10.00
7/9/2025	RXST RxSight	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$17.00 ➝ $9.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
NPCE NeuroPace	$88.57M	3.23	N/A	N/A	$0.59 per share	14.68
RXST RxSight	$147.06M	2.36	N/A	N/A	$6.79 per share	1.25
VANI Vivani Medical	N/A	N/A	N/A	N/A	$0.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	N/A
NPCE NeuroPace	-$27.14M	-$0.84	N/A	N/A	N/A	-29.29%	-168.61%	-25.48%	N/A
RXST RxSight	-$27.45M	-$0.80	N/A	N/A	N/A	-21.93%	-11.56%	-10.31%	11/6/2025 (Estimated)
VANI Vivani Medical	-$23.49M	-$0.45	N/A	N/A	N/A	N/A	-194.66%	-68.64%	N/A

Latest VANI, RXST, NPCE, and CATX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	VANI Vivani Medical	-$0.10	-$0.12	-$0.02	-$0.12	N/A	N/A
8/12/2025	Q2 2025	NPCE NeuroPace	-$0.24	-$0.26	-$0.02	-$0.26	$23.08 million	$23.52 million
8/7/2025	Guidance Update	RXST RxSight	-$0.04	-$0.08	-$0.04	-$0.29	$39.78 million	$33.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
RXST RxSight	N/A	N/A	N/A	N/A	N/A
VANI Vivani Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
NPCE NeuroPace	3.02	5.47	4.51
RXST RxSight	N/A	13.93	12.70
VANI Vivani Medical	N/A	1.30	1.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
NPCE NeuroPace	78.83%
RXST RxSight	78.78%
VANI Vivani Medical	6.78%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
NPCE NeuroPace	20.50%
RXST RxSight	9.57%
VANI Vivani Medical	46.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
NPCE NeuroPace	170	33.08 million	26.30 million	Optionable
RXST RxSight	220	40.92 million	37.00 million	Optionable
VANI Vivani Medical	20	59.24 million	31.76 million	Optionable

VANI, RXST, NPCE, and CATX Headlines

Recent News About These Companies

Vivani Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference on Innovative Drug Implant Technology

August 20 at 8:51 AM | quiverquant.comQ

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

August 20 at 8:30 AM | globenewswire.com

Fido get fat? Ozempic for dogs could hit the market in three years

August 19 at 7:29 PM | msn.com

Vivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings Miss

August 15, 2025 | marketbeat.com

Vivani Medical (NASDAQ:VANI) Announces Quarterly Earnings Results

August 15, 2025 | marketbeat.com

Vivani closes $10M financing, advances GLP-1 implant

August 14, 2025 | drugdeliverybusiness.comD

Vivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 14, 2025 | finanznachrichten.de

Vivani Medical (NASDAQ:VANI) Stock Price Down 0.8% Following Weak Earnings

August 14, 2025 | americanbankingnews.com

Vivani Medical Reports Q2 2025 Results and $10M Financing

August 13, 2025 | tipranks.com

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...

August 13, 2025 | bakersfield.comB

Vivani Medical Secures $10M Through Share Purchase Agreement

August 13, 2025 | msn.com

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 13, 2025 | globenewswire.com

Vivani Medical (VANI) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Vivani Medical, Inc. (NASDAQ:VANI) Sees Large Growth in Short Interest

August 2, 2025 | marketbeat.com

Vivani Medical (NASDAQ:VANI) Shares Up 0.6% - Here's What Happened

July 23, 2025 | marketbeat.com

3 Penny Stocks With Market Caps Over $30M To Consider

July 16, 2025 | finance.yahoo.com

Vivani Medical Insiders Added US$5.29m Of Stock To Their Holdings

June 30, 2025 | uk.finance.yahoo.com

Vivani Medical shareholders elect board and approve key proposals at annual meeting - Investing.com

June 27, 2025 | investing.com

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

June 11, 2025 | manilatimes.netM

Vivani Medical to Present at the 2025 BIO International Convention

June 11, 2025 | finance.yahoo.com

Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit

June 2, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI, RXST, NPCE, and CATX Company Descriptions

Perspective Therapeutics NYSE:CATX

$3.38 -0.04 (-1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$3.47 +0.09 (+2.54%)

As of 05:18 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

NeuroPace NASDAQ:NPCE

$8.66 +0.41 (+4.97%)

Closing price 04:00 PM Eastern

Extended Trading

$8.56 -0.10 (-1.15%)

As of 05:08 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

RxSight NASDAQ:RXST

$8.45 -0.36 (-4.09%)

Closing price 04:00 PM Eastern

Extended Trading

$8.51 +0.06 (+0.70%)

As of 05:25 PM Eastern

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Vivani Medical NASDAQ:VANI

$1.22 +0.01 (+0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 0.00 (-0.41%)

As of 04:10 PM Eastern

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time